clinical trial · NCT06433557
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Ascendis Pharma Growth Disorders A/S·phase2·active not recruiting·n = 22
AchondroplasiaCombination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
brief summary
This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.
started
Jul 26, 2024
primary completion
Nov 14, 2025
completion
Nov 1, 2027
last updated
Feb 18, 2026
official title
A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol